More from Stocks
These recently downgraded names are displaying both quantitative and technical deterioration.
After a deal with GlaxoSmithKline, the small-cap antibiotic developer Spero Therapeutics should get a shot as an options play.
Let's review three high-yield business development companies.
Here are six ways to handle the two biggest risks.
The hurt Fed Chair Jerome Powell has been talking about so much lately is no longer an abstract concept on Wall Street. But with the horrible action comes opportunities.